Pulmonary ResectionNCT07042893
Effects of Pulmonary Resection on Right Ventricular Function
An observational study of Pulmonary Resection and Right Ventricular Function, run by Çağrı Özdemir at 1 site in Turkey (Türkiye).
Trial summary
Lung resection is associated with high postoperative morbidity and mortality and leads to a significant long-term decrease in functional capacity, particularly due to cardiorespiratory complications. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Pulmonary Resection, Right Ventricular Function, Echocardiography
- How many people
- 33 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Apr 2025to 15 May 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients aged 18 to 80 years scheduled to undergo lung resection surgery.
Who may be able to join
- Adults aged 18 to 80 years
- ASA classification I-III
- Patients scheduled to undergo lung resection in thoracic surgery
Who cannot join
- Patients with arrhythmia
- Patients using antiarrhythmic drugs
- Patients with renal failure requiring hemodialysis
- Patients with a history of previous lung surgery
- Patients with valvular heart disease
- Patients with a history of angina pectoris or myocardial infarction within the past month
- Patients with FEV1/FVC ratio below 60%
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Gazi University Faculty of Medicine, Ankara
Ankara, Yenimahalle, 06500
About this study
Official title: Echocardiographic Assessment of Right Ventricular Function After Pulmonary Resection
Lung resection is associated with high postoperative morbidity and mortality and leads to a significant long-term decrease in functional capacity, particularly due to cardiorespiratory complications. One of the contributing factors to this functional decline is the postoperative reduction in right ventricular function. Due to the anatomical proximity and interactions, right ventricular function is evaluated by echocardiography following lung resection. The pulmonary artery pressure (PAP)/tricuspid annular plane systolic excursion (TAPSE) ratio is a parameter that provides a more comprehensive assessment of right heart function by evaluating both right ventricular systolic function and pulmonary artery pressure. In this study, investigators aimed to evaluate changes in right heart function by performing preoperative and postoperative echocardiographic assessments in participants undergoing lung resection, focusing on PAP/TAPSE ratios.
- Conditions
- Pulmonary Resection, Right Ventricular Function, Echocardiography, Cardiothoracic Anesthesia
- Keywords
- pulmonary resection, right ventricular function, echocardiography, cardiothoracic anesthesia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Group 1 | In this study, a single group (Group 1) will be defined, and patients scheduled for lung resection who agree to participate will be included. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Echocardiographic Assessment: TAPSE/PASP Ratio
Patients will undergo transthoracic echocardiographic evaluation preoperatively, on postoperative days 2-4, and at postoperative month 2. The TAPSE/PASP ratio will be calculated and recorded in mm/mmHg as a non-invasive surrogate of right ventricular-pulmonary arterial coupling.
Measured: Preoperatively, on postoperative days 2-4, and at postoperative month 2
Echocardiographic Assessment: Tricuspid Annular Plane Systolic Excursion (TAPSE)
Patients will undergo transthoracic echocardiographic evaluation preoperatively, on postoperative days 2-4, and at postoperative month 2. TAPSE will be measured and recorded in millimeters (mm).
Measured: Preoperatively, on postoperative days 2-4, and at postoperative month 2
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jun 2025
- Study start1 Apr 2025
- Primary completion24 Apr 2026
- Study completion15 May 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pulmonary ResectionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 33 participants (actual)
Sponsor and investigators
- Lead sponsor
- Çağrı Özdemir
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Çağrı Özdemir, Gazi University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07042893
- Sponsor's protocol ID
- 2024 - 1160
- Status last verified
- Aug 2026
- First submitted
- 20 Jun 2025
- Last updated
- 20 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Echocardiographic Assessment of Right Ventricular Function After Pulmonary Resection
- ClinicalTrials.gov ID
- NCT07042893
- Acronym / sponsor ID
- 2024 - 1160
- Conditions
- Pulmonary Resection, Right Ventricular Function, Echocardiography, Cardiothoracic Anesthesia
- Keywords
- pulmonary resection, right ventricular function, echocardiography, cardiothoracic anesthesia
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 33 participants (actual)
- Lead sponsor
- Çağrı ÖzdemirUniversity, hospital or other
- Study start
- 1 Apr 2025 (actual)
- Primary completion
- 24 Apr 2026 (actual)
- Study completion
- 15 May 2026 (actual)
- First posted
- 29 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Lung resection is associated with high postoperative morbidity and mortality and leads to a significant long-term decrease in functional capacity, particularly due to cardiorespiratory complications. One of the contributing factors to this functional decline is the postoperative reduction in right ventricular function. Due to the anatomical proximity and interactions, right ventricular function is evaluated by echocardiography following lung resection. The pulmonary artery pressure (PAP)/tricuspid annular plane systolic excursion (TAPSE) ratio is a parameter that provides a more comprehensive assessment of right heart function by evaluating both right ventricular systolic function and pulmonary artery pressure. In this study, investigators aimed to evaluate changes in right heart function by performing preoperative and postoperative echocardiographic assessments in participants undergoing lung resection, focusing on PAP/TAPSE ratios.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Group 1 | – | –In this study, a single group (Group 1) will be defined, and patients scheduled for lung resection who agree to participate will be included. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients aged 18 to 80 years scheduled to undergo lung resection surgery.
Key inclusion criteria (3 listed)
- Adults aged 18 to 80 years
- ASA classification I-III
- Patients scheduled to undergo lung resection in thoracic surgery
Key exclusion criteria (7 listed)
- Patients with arrhythmia
- Patients using antiarrhythmic drugs
- Patients with renal failure requiring hemodialysis
- Patients with a history of previous lung surgery
- Patients with valvular heart disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Echocardiographic Assessment: TAPSE/PASP Ratio
Time frame: Preoperatively, on postoperative days 2-4, and at postoperative month 2
Patients will undergo transthoracic echocardiographic evaluation preoperatively, on postoperative days 2-4, and at postoperative month 2. The TAPSE/PASP ratio will be calculated and recorded in mm/mmHg as a non-invasive surrogate of right ventricular-pulmonary arterial coupling.
Echocardiographic Assessment: Tricuspid Annular Plane Systolic Excursion (TAPSE)
Time frame: Preoperatively, on postoperative days 2-4, and at postoperative month 2
Patients will undergo transthoracic echocardiographic evaluation preoperatively, on postoperative days 2-4, and at postoperative month 2. TAPSE will be measured and recorded in millimeters (mm).
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Pulmonary Resection
RecruitingPhase 3
A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
Non-Small Cell Lung Cancer
RecruitingPhase 3
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma
Active, not recruitingPhase 3
Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy
Pulmonary Embolism
Recruiting
Longitudinal AI-Assisted Management of Indeterminate Pulmonary Nodules
Pulmonary Nodules, Lung Neoplasms
RecruitingPhase 3
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
Non-small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pulmonary Resection and Right Ventricular Function, run by Çağrı Özdemir at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Echocardiographic Assessment: TAPSE/PASP Ratio (time frame: Preoperatively, on postoperative days 2-4, and at postoperative month 2). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Aug 2026.